|
|
||||||||
Oncology-Clinical Diagnosis: Solid TumorsClinical Diagnosis-Solid Tumors Posters |
1 Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba-shi, Japan; ; 2 First Dept. of Oral & Maxillofacial surgery, Tsurumi University, Yokohama-shi, Japan
1491
Objectives: To determine if Cu-62 labeled diacetyl-bis (N (4)-methylthiosemicarbazone); (Cu-62-ATSM) imaging of tumor hypoxia is associated with C-11-methionine imaging of amino acid metabolism in cervical cancer.
Methods: PET/CT was performed in ten patients with cervical cancer for evaluation of both tumor hypoxia using Cu-62-ATSM and amino acid metabolism using C-11-Methionine (MET). Histologically confirmed six squamous cell carcinoma and four adenocarcima were enrolled in this study. All PET/CT studies were underwent before any treatment. Distribution of Cu-62-ATSM in tumor was compared with that of MET using the fused images registered automatically by PMOD software based on Mutual Information. The two-group system was evaluated the distribution of uptake as Matched (mostly matched with each other) and Mismatched (with each other). Tumor uptake of each tracer was also analyzed semi-quantitatively by Tumor-to-Normal-Tissue-Ratio (TNR).
Results: Matched and Mismatched-groups were 1 case (10%) and 9 cases (90%), respectively. In Mismatched-group, Cu-62-ATSM tend to accumulate around the distal margin of high MET uptake area in the tumor. This might represent different metabolic information of tumor. Mean TNR was 9.3 in MET and 3.8 in Cu-62-ATSM, and thus image contrast between tumor and surrounding normal tissue was higher in MET PET/CT image than Cu-62-ATSM PET/CT image.
Conclusions: Cu-62-ATSM and MET showed different distribution in most cases of cervical cancer. Cervical cancer had a greater tendency for the uptake of MET than Cu-62-ATSM and so the image contrast in MET PET/CT was higher than that of Cu-62-ATSM.
| ||||||||||||||||||||||||||||